drugset / Trial / NCT00432614
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs. placebo in patients with Major Depressive Disorder who are on concomitant treatment with escitalopram. The secondary objective of this study is to document clinical safety and tolerability of SR58611A in association with escitalopram.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | amibegron | Small molecule | 350 mg | Oral |
| Background | Escitalopram | Small molecule | 10 mg | Oral |